Expression of synovial fluid and articular cartilage VIP in human osteoarthritic knee: A new indicator of disease severity?

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1607-1612

  Jiang, Wei ^a   Gao, Shu Guang ^a   Chen, Xia Guang ^c   Xu, Xiao Cao ^a   Xu, Mai ^a   Luo, Wei ^a   Tu, Min ^a   Zhang, Fang Jie ^a   Zeng, Chao ^a   Lei, Guang Hua ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c People's Hospital of Ganzhou   (China)

Author keywords

Articular cartilage; Osteoarthritis; Synovial fluid; Vasoactive intestinal peptide

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ABOVE KNEE AMPUTATION; ADULT; ARTICLE; ARTICULAR CARTILAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INJURY; KNEE OSTEOARTHRITIS; MALE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; SCORING SYSTEM; SYNOVIAL FLUID; SYNOVIAL FLUID LEVEL; TISSUE LEVEL; TOTAL KNEE REPLACEMENT;

AGED; CARTILAGE, ARTICULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84870688351     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.08.020     Document Type: Article

References (27)

1. Zhang Y., Jordan J.M. Epidemiology of osteoarthritis. Clin Geriatr Med 2010, 26(3):355-369.
2. Said S.I., Mutt V.A. Peptide fraction from lung tissue with prolonged vasodilatory activity. Scand J Clin Lab Invest Suppl 1969, 107:51-56.
3. Rosignoli F., Torroba M., Juarranz Y., García-Gómez M., Martinez C., Gomariz R.P., et al. VIP and tolerance induction in autoimmunity. Ann N Y Acad Sci 2006, 1070:525-530.
4. Li H., Mei Y., Wang Y., Xu L. Vasoactive intestinal peptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006, 26:430-437.
5. Anderson P., Gonzalez-Rey E. Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol Cell Biol 2010, 30(10):2537-2551.
6. Smalley S.G., Barrow P.A., Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 2009, 157(2):225-234.
7. MacKenzie C.J., Lutz E.M., McCulloch D.A., Mitchell R., Harmar A.J. Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism. Ann NY Acad Sci 1996, 26:579-584.
8. Dickson L., Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther 2009, 121(3):294-316.
9. Delgado M., Abad C., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by down-regulating both autoimmune and inflammatory components of the disease. Nat Med 2001, 7:563-568.
10. Juarranz Y., Abad C., Martinez C., Arranz A., Gutierrez-Cañas I., Rosignoli F., et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005, 7:1034-1045.
11. Juarranz M.G., Santiago B., Torroba M., Gutierrez-Canas I., Palao G., Galindo M., et al. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 2004, 43:416-422.
12. Gutiérrez-Cañas I., Juarranz Y., Santiago B., Martínez C., Gomariz R.P., Pablos J.L., et al. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun 2008, 22:312-317.
13. Juarranz Y., Gutierrez-Canas I., Santiago B., Carrion M., Pablos J.L., Gomariz R.P. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008, 58:1086-1095.
14. Juarranz Y., Gutiérrez-Cañas I., Arranz A., Martínez C., Abad C., Leceta J., et al. VIP decreases TLR4 expression induced by LPS and TNF-α treatment in human synovial fibroblasts. Ann N Y Acad Sci 2006, 1070:359-364.
15. Carrión M., Juarranz Y., Pérez-García S., Jimeno R., Pablos J.L., Gomariz R.P., et al. RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts immune regulation by vasoactive intestinal peptide. Arthritis Rheum 2011, 63(6):1626-1636.
16. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
17. Kellgren J.H., Lawrence J.S. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957, 16:494-502.
18. van der Sluijs J.A., Geesink R.G., van der Linden A.J., Bulstra S.K., Kuyer R., Drukker J. The reliability of the Mankin score for osteoarthritis. J Orthop Res 1992, 10(1):58-61.
19. Arranz A., Juarranz Y., Leceta J., Gomariz R.P., Martínez C. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 2008, 29(6):948-956.
20. Delgado M., Toscano M.G., Benabdellah K., Cobo M., O'Valle F., Gonzalez-Rey E., et al. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthritis Rheum 2008, 58(4):1026-1037.
21. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003, 124(4):961-971.
22. Pérez-García S., Juarranz Y., Carrión M., Gutiérrez-Cañas I., Margioris A., Pablos J.L., et al. Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts effect of vasoactive intestinal peptide. J Cell Physiol 2011, 226(12):3261-3269.
23. Delgado M., Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids 2011, 10.1007/s00726-011-1184-8.
24. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NFΚB, NF-AT, and early growth factors 2/3. J Immunol 2001, 166:1028-1040.
25. Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. Biochem Biophys Res Commun 2002, 293(2):771-776.
26. Onuoha G., Alpar K., Jones I. Vasoactive intestinal peptide and nitric oxide in the acute phase following burns and trauma. Burns 2001 Feb, 27(1):17-21.
27. Henriksen J.H., Bülow J.B., Schaffalitzky de Muckadell O., et al. Do substance P and vasoactive intestinal polypeptide (VIP) play a role in the acute occlusive or chronic ischaemic vasodilation in man?. Clin Physiol 1986 Apr, 6(2):163-170.